{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8d84b145",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "a42de727",
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "client = OpenAI()\n",
    "\n",
    "def call_openai():\n",
    "    response = client.responses.create(\n",
    "    model=\"o4-mini\",\n",
    "    input=[\n",
    "        {\n",
    "        \"role\": \"developer\",\n",
    "        \"content\": [\n",
    "            {\n",
    "            \"type\": \"input_text\",\n",
    "            \"text\": \"You are a highly analytical reasoning model. Your task is to generate a structured dataset that links each of the following biomarkers to relevant diseases, capturing both qualitative and quantitative aspects of their relationships.\\n\\nBiomarkers:\\n  • Amyloid Beta:\\n    – Aβ42/40 ratio\\n    – Amyloid-related imaging abnormalities (ARIA)\\n    – Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)\\n    – Stable isotope labeling kinetics (SILK)\\n    – Standardized uptake value ratio / Centiloids (SUVR/CL)\\n    – Soluble amyloid precursor protein (sAPP)\\n    – Oligomeric Aβ (oAβ)\\n  • Tau:\\n    – Phosphorylated tau-181 (p-tau181)\\n    – Phosphorylated tau-205 (p-tau205)\\n    – Phosphorylated tau-217 (p-tau217)\\n    – Phosphorylated tau-231 (p-tau231)\\n  • APOE, Lipids, and Lipoprotein Receptors:\\n    – Apolipoprotein A1 (ApoA1)\\n    – Apolipoprotein C3 (ApoC3)\\n    – Fatty acid-binding protein 3 (FABP3)\\n    – Myelin\\n  • Inflammation:\\n    – Interleukin 1 beta (IL-1β)\\n    – Interleukin 6 (IL-6)\\n    – Interleukin 8 (IL-8)\\n    – Interleukin 10 (IL-10)\\n    – IL-12/23p40 subunit\\n\\nDiseases to consider (examples; feel free to expand):\\n  – Alzheimer’s disease (AD)\\n  – Mild cognitive impairment (MCI)\\n  – Vascular dementia (VaD)\\n  – Frontotemporal dementia (FTD)\\n  – Parkinson’s disease (PD)\\n  – Multiple sclerosis (MS)\\n  – Other neuroinflammatory or neurodegenerative conditions\\n\\n**Output specification**  \\nReturn a **JSON array** where each entry corresponds to one biomarker–disease pair, with these fields:\\n\\n```json\\n{\\n  \\\"summary\\\":  \\\"<biomarker> resulted in <relationship> in <disease name> with <strength> strength.\\n}\\n\"\n",
    "            }\n",
    "        ]\n",
    "        },\n",
    "        {\n",
    "        \"role\": \"user\",\n",
    "        \"content\": [\n",
    "            {\n",
    "            \"type\": \"input_text\",\n",
    "            \"text\": \"Base your notes and reference fields on well-established findings. Generate as much examples as possible. No need to include a reference section\"\n",
    "            }\n",
    "        ]\n",
    "        },\n",
    "        {\n",
    "        \"type\": \"reasoning\",\n",
    "        \"id\": \"rs_68354478223881988638cdf5bb7ba1af0af0931a4b636060\",\n",
    "        \"summary\": []\n",
    "        },\n",
    "        {\n",
    "        \"id\": \"msg_683544937c288198a3756351dc5232630af0931a4b636060\",\n",
    "        \"role\": \"assistant\",\n",
    "        \"content\": [\n",
    "            {\n",
    "            \"type\": \"output_text\",\n",
    "            \"text\": \"{\\n  \\\"biomarker\\\": \\\"Aβ42/40 ratio\\\",\\n  \\\"relationship\\\": \\\"decreased CSF ratio\\\",\\n  \\\"disease_name\\\": \\\"Alzheimer's disease\\\",\\n  \\\"strength\\\": \\\"strong\\\"\\n}\"\n",
    "            }\n",
    "        ]\n",
    "        }\n",
    "    ],\n",
    "    text={\n",
    "        \"format\": {\n",
    "        \"type\": \"json_schema\",\n",
    "        \"name\": \"data_list\",\n",
    "        \"strict\": True,\n",
    "        \"schema\": {\n",
    "            \"type\": \"object\",\n",
    "            \"properties\": {\n",
    "            \"data\": {\n",
    "                \"type\": \"array\",\n",
    "                \"description\": \"A list of objects.\",\n",
    "                \"items\": {\n",
    "                \"type\": \"object\",\n",
    "                \"required\": [\n",
    "                    \"disease_name\",\n",
    "                    \"summary\"\n",
    "                ],\n",
    "                \"properties\": {\n",
    "                    \"disease_name\": {\n",
    "                    \"type\": \"string\",\n",
    "                    \"description\": \"Name of the disease associated with the biomarker.\"\n",
    "                    },\n",
    "                    \"summary\": {\n",
    "                    \"type\": \"string\",\n",
    "                    \"description\": \"<biomarker> resulted in <relationship> in <disease_name> with <strength> strength.\"\n",
    "                    }\n",
    "                },\n",
    "                \"additionalProperties\": False\n",
    "                }\n",
    "            }\n",
    "            },\n",
    "            \"required\": [\n",
    "            \"data\"\n",
    "            ],\n",
    "            \"additionalProperties\": False\n",
    "        }\n",
    "        }\n",
    "    },\n",
    "    reasoning={\n",
    "        \"effort\": \"medium\"\n",
    "    },\n",
    "    tools=[],\n",
    "    store=True\n",
    "    )\n",
    "\n",
    "    return response.output_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ac461113",
   "metadata": {},
   "outputs": [],
   "source": [
    "res = []\n",
    "for i in range(5):\n",
    "    res.append(call_openai())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "d4bf7537",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'{\"data\":[\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Aβ42/40 ratio resulted in decreased CSF ratio in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Aβ42/40 ratio resulted in decreased CSF ratio in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Vascular dementia\",\"summary\":\"Aβ42/40 ratio resulted in no significant change in Vascular dementia with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Amyloid-related imaging abnormalities (ARIA) resulted in increased incidence post-immunotherapy in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Amyloid-related imaging abnormalities (ARIA) resulted in minimal incidence post-immunotherapy in Mild cognitive impairment with weak strength.\"},\\n  {\"disease_name\":\"Frontotemporal dementia\",\"summary\":\"Amyloid-related imaging abnormalities (ARIA) resulted in rare observations in Frontotemporal dementia with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) resulted in increased enzymatic activity in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) resulted in elevated activity in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) resulted in unchanged activity in Parkinson\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Stable isotope labeling kinetics (SILK) resulted in increased Aβ production rate in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Stable isotope labeling kinetics (SILK) resulted in slightly elevated Aβ production in Mild cognitive impairment with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Standardized uptake value ratio / Centiloids (SUVR/CL) resulted in elevated amyloid PET uptake in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Standardized uptake value ratio / Centiloids (SUVR/CL) resulted in moderate PET uptake in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Vascular dementia\",\"summary\":\"Standardized uptake value ratio / Centiloids (SUVR/CL) resulted in detectable uptake in mixed pathology cases of Vascular dementia with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Soluble amyloid precursor protein (sAPP) resulted in increased sAPPβ levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Soluble amyloid precursor protein (sAPP) resulted in no significant alteration in Parkinson\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Oligomeric Aβ (oAβ) resulted in elevated oligomer levels in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Oligomeric Aβ (oAβ) resulted in increased oligomer levels in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Frontotemporal dementia\",\"summary\":\"Oligomeric Aβ (oAβ) resulted in minimal change in Frontotemporal dementia with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Phosphorylated tau-181 (p-tau181) resulted in elevated CSF levels in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Phosphorylated tau-181 (p-tau181) resulted in increased CSF levels in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Frontotemporal dementia\",\"summary\":\"Phosphorylated tau-181 (p-tau181) resulted in unchanged levels in Frontotemporal dementia with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Phosphorylated tau-205 (p-tau205) resulted in elevated CSF levels in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Phosphorylated tau-205 (p-tau205) resulted in moderate CSF elevations in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Phosphorylated tau-217 (p-tau217) resulted in markedly elevated CSF levels in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Phosphorylated tau-217 (p-tau217) resulted in elevated CSF levels in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Phosphorylated tau-231 (p-tau231) resulted in elevated CSF levels in Alzheimer\\'s disease with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Phosphorylated tau-231 (p-tau231) resulted in moderate CSF elevations in Mild cognitive impairment with moderate strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Apolipoprotein A1 (ApoA1) resulted in decreased plasma levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Apolipoprotein A1 (ApoA1) resulted in slight plasma decrease in Parkinson\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Apolipoprotein C3 (ApoC3) resulted in elevated plasma levels in Alzheimer\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Apolipoprotein C3 (ApoC3) resulted in no significant change in Multiple sclerosis with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Fatty acid-binding protein 3 (FABP3) resulted in increased CSF levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Fatty acid-binding protein 3 (FABP3) resulted in elevated CSF levels in Parkinson\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Fatty acid-binding protein 3 (FABP3) resulted in no significant change in Multiple sclerosis with weak strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Myelin resulted in decreased white matter integrity on imaging in Multiple sclerosis with strong strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Myelin resulted in increased CSF myelin basic protein indicating demyelination in Multiple sclerosis with strong strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Myelin resulted in mild white matter loss in Alzheimer\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Interleukin 1 beta (IL-1β) resulted in elevated CSF levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Interleukin 1 beta (IL-1β) resulted in increased lesion-associated levels in Multiple sclerosis with strong strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Interleukin 1 beta (IL-1β) resulted in slight elevation in Parkinson\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Interleukin 6 (IL-6) resulted in elevated CSF levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Interleukin 6 (IL-6) resulted in elevated levels in Multiple sclerosis with strong strength.\"},\\n  {\"disease_name\":\"Mild cognitive impairment\",\"summary\":\"Interleukin 6 (IL-6) resulted in mild CSF elevation in Mild cognitive impairment with weak strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Interleukin 8 (IL-8) resulted in elevated CSF levels in Alzheimer\\'s disease with moderate strength.\"},\\n  {\"disease_name\":\"Parkinson\\'s disease\",\"summary\":\"Interleukin 8 (IL-8) resulted in moderate elevation in Parkinson\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Interleukin 8 (IL-8) resulted in elevated levels in Multiple sclerosis with moderate strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"Interleukin 10 (IL-10) resulted in decreased CSF levels in Alzheimer\\'s disease with weak strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"Interleukin 10 (IL-10) resulted in elevated regulatory response in Multiple sclerosis with moderate strength.\"},\\n  {\"disease_name\":\"Multiple sclerosis\",\"summary\":\"IL-12/23p40 subunit resulted in elevated CSF levels in Multiple sclerosis with moderate strength.\"},\\n  {\"disease_name\":\"Alzheimer\\'s disease\",\"summary\":\"IL-12/23p40 subunit resulted in slight elevation in Alzheimer\\'s disease with weak strength.\"}\\n]}'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "f843f6ef",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "for item in res:\n",
    "    parsed = json.loads(item)\n",
    "    with open('results.json', 'a') as f:\n",
    "        json.dump(parsed, f)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "nlp_ml",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
